- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01871350
Nutrition Intervention During Chemotherapy
Effects of Chemotherapy and Nutritional Intervention on Gut Function and Metabolism in Cancer
Weight loss and muscle wasting commonly occurs in patients with cancer, negatively influencing their quality of life, treatment response and survival. Weight loss has been reported as a side effect of chemotherapy treatment in cancer. Weight changes may be the consequence of energy imbalance and disturbances in protein metabolism (through different factors linked with chemotherapy), such as reduced caloric and protein intake (partly related to depression), poor treatment tolerance, hormonal alterations, systemic inflammation etc. This results in body composition modifications in favor of fat gain and/or lean body mass loss in early stage cancer and loss of both fat mass and lean mass in advanced cancer. Depletion of lean tissue in cancer patients is related to short survival, and decreased skeletal muscle mass and function may result in fatigue and inactivity, which contributes to fat mass changes and can be responsible for chemo-toxicity and increased mortality.
Gains in muscle mass are difficult to achieve in cancer unless specific metabolic abnormalities are targeted. Recently, the investigators observed that essential amino acid mixtures (EAA) are able to induce protein anabolism in patients with stage III and IV non-small cell lung cancer. Previous experimental research and clinical studies in cachectic conditions (including cancer) indicate that polyunsaturated fatty acids (PUFA) are able to attenuate protein degradation by improving the anabolic response to feeding and by decreasing the acute phase response. Eicosapentaenoic acid (EPA) (in combination with docosahexaenoic acid (DHA)) has been shown to effectively inhibit weight loss in several disease states; however, weight and muscle mass gain was not present or minimal. Recent studies examining the effect of fish oil supplementation in relation to chemotherapy have been inconclusive but found potential beneficial effects on physical performance and increased efficacy of first-line chemotherapy in patients with non-small cell lung cancer.
It is the investigators' hypothesis that supplementation with milk protein (containing essential amino acids) carbohydrate (CHO) mixture in combination with fish oil supplementation will target the metabolic alterations in cancer patients receiving chemotherapy, attenuating the negative effects of chemotherapy on gut function, muscle mass and muscle function, and cognition; and leading to reduced toxicity from chemotherapy.
Study Overview
Status
Intervention / Treatment
Detailed Description
For the cancer subjects, the study involves 1 test day prior to a chemotherapy treatment, a 10-week (± 2 weeks) nutritional intervention period at home starting the first day of the chemotherapy treatment, and one test day after this intervention. Chemotherapy in general lasts at least a few months. Recent studies indicate that a 10-week nutritional supplementation period should be long enough to reach significant improvements in nutritional and clinical outcome parameters during chemotherapy. Throughout these 10 weeks the cancer subjects will take the supplements at home. Cancer subjects will be randomly assigned to receive either fish oil or a placebo and protein or a placebo and will take these supplements daily throughout 10 weeks during chemotherapy.
For the healthy subjects, the study will involve one test day (approx. 8 hours).
On the test days, the response to a protein meal will be examined and subjects will receive a mixture of amino acids which are a little bit heavier than normal, called stable isotopes. Subjects will also ingest a sugar drink to assess gut permeability. In total, approximate 120 ml of blood will be drawn on each test day to assess outcome measures. The investigators' will also collect urine over these 8 hours, and cancer subjects are asked to collect a fecal sample the day before the test day.
After completing the nutritional intervention study, cancer subjects will be monitored for up to 6 months via 2 phone calls and through their physician as part of clinical care. Between 6 months and 2 years after completion of the study, information about disease progression (survival) will be obtained from the physician.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
College Station, Texas, United States, 77843
- Texas A&M University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria cancer subjects:
- Diagnosed with cancer
- Scheduled for chemotherapy or chemoradiotherapy
- Ability to sign informed consent
- Age 18y and older
- Ability to lie in supine position for 7 hours
Inclusion criteria healthy subjects:
- Healthy male or female according to the investigator's or appointed staff's judgment
- Age 18 years or older
- No diagnosis of cancer
Exclusion Criteria
- Presence of fever within the last 3 days
- BMI > 38 kg/m2 (healthy controls only)
- Untreated metabolic diseases including hepatic or renal disorder
- Presence of acute illness or metabolically unstable chronic illness
- Use of protein or amino acid containing nutritional supplements within 5 days of first test day
- Known hypersensitivity to fish and/or shellfish, Swanson EFAs Super EPA Fish oil or any of its ingredients, Swanson EFAs Certified Organic Extra Virgin Olive oil or any of its ingredients, Smartfish Nutrifriend or any of its ingredients (Cancer subjects only)
- Use of supplements containing EPA+DHA 3 months prior to the first test day
- Any other condition according to the PI or nurse that would interfere with the study or safety of the patient
- Failure to give informed consent
- (Possible) pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Protein and Fish Oil
Low Dose (FFM <49kg): 30.00g milk protein + 12.75g maltodextrin and 6g fish oil High dose (FFM >49kg): 40.00g milk protein + 17.00g maltodextrin and 8g fish oil |
|
|
Experimental: Protein
Low Dose (FFM <49kg): 30.00g milk protein + 12.75g maltodextrin and 6g olive oil High dose (FFM >49kg): 40.00g milk protein + 17.00g maltodextrin and 8g olive oil |
|
|
Placebo Comparator: Placebo
Low Dose (FFM <49kg): 12.75g maltodextrin and 6g olive oil High dose (FFM >49kg): 17.00g maltodextrin and 8g olive oil |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Net whole-body protein synthesis
Time Frame: Acutely before and after 4 hours of feeding and the change after 10 weeks of supplementation
|
The acute change in whole-body protein synthesis rate before and after intake of meal is determined on the first test day for the healthy control group and the cancer group.
Secondly, the cancer patients in all 3 intervention arms are also measured after 10 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.
|
Acutely before and after 4 hours of feeding and the change after 10 weeks of supplementation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Citrulline Rate of appearance
Time Frame: In the postabsorptive state for 4h on the first test day and the change on the second test day after 10 weeks of supplementation
|
Plasma enrichment of citrulline is determined on the first test day for the healthy control group and the cancer group.
Secondly, the cancer patients in all 3 intervention arms are also measured after 10 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.
|
In the postabsorptive state for 4h on the first test day and the change on the second test day after 10 weeks of supplementation
|
|
Glucose absorption
Time Frame: 7 hours during the test day and the change after 10 weeks of supplementation
|
Recovery of 3-O-Methyl-D-glucose in the urine is measured on the first test day for the healthy control group and the cancer group.
Secondly, the cancer patients in all 3 intervention arms are also measured after 10 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.
|
7 hours during the test day and the change after 10 weeks of supplementation
|
|
Gut permeability
Time Frame: 7 hours during the test day and the change after 10 weeks of supplementation
|
Recovery of rhamnose/lactulose in urine is measured on the first test day for the healthy control group and the cancer group.
Secondly, the cancer patients in all 3 intervention arms are also measured after 10 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.
|
7 hours during the test day and the change after 10 weeks of supplementation
|
|
Skeletal and respiratory muscle strength
Time Frame: In the postabsorptive state on the first test day and the change on the second test day after 10 weeks of supplementation
|
Difference in leg strength and fatigue, handgrip strength and fatigue, and inspiratory and expiratory pressure between heart failure patients and healthy controls on test day 1.
The cancer patients in all 3 intervention arms are also measured after 10 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.
|
In the postabsorptive state on the first test day and the change on the second test day after 10 weeks of supplementation
|
|
Cognitive function
Time Frame: On the first test day and the change on the second test day after 10 weeks of supplementation
|
Outcome of neuro-psychological tests in heart failure patients and healthy controls in relation to the tryptophan metabolism.
The cancer patients in all 3 intervention arms are also measured after 10 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.
|
On the first test day and the change on the second test day after 10 weeks of supplementation
|
|
Fatty acid digestion after feeding
Time Frame: Acutely after 4 hours of feeding and the change after 10 weeks of supplementation
|
Enrichment in palmitic acid and tripalmitin fatty acids in plasma in response to a meal is measured on the first test day in for the healthy control group and the cancer group.
Secondly, the cancer patients in all 3 intervention arms are also measured after 10 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.
|
Acutely after 4 hours of feeding and the change after 10 weeks of supplementation
|
|
Protein digestion after feeding
Time Frame: Acutely after 4 hours of feeding and the change after 10 weeks of supplementation
|
Ratio enrichment free phenylalanine vs phenylalanine from protein spirulina in response to a meal is measured on the first test day for the healthy control group and the cancer group.
Secondly, the cancer patients in all 3 intervention arms are also measured after 10 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.
|
Acutely after 4 hours of feeding and the change after 10 weeks of supplementation
|
|
Whole body collagen breakdown rate
Time Frame: In the postabsorptive state on the first test day and the change on the second test day after 10 weeks of supplementation
|
Hydroxyproline enrichment in plasma is measured on the first test day for the healthy control group and the cancer group.
Secondly, the cancer patients in all 3 intervention arms are also measured after 10 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.
|
In the postabsorptive state on the first test day and the change on the second test day after 10 weeks of supplementation
|
|
Tryptophan turnover rate
Time Frame: In the postabsorptive state on the first test day and the change on the second test day after 10 weeks of supplementation
|
Tryptophan enrichment in plasma is measured on the first test day for the healthy control group and the cancer group.
Secondly, the cancer patients in all 3 intervention arms are also measured after 10 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.
|
In the postabsorptive state on the first test day and the change on the second test day after 10 weeks of supplementation
|
|
Insulin response to feeding
Time Frame: Before and acutely after 4 hours of feeding and the change after 10 weeks of supplementation
|
The acute change in insulin levels before and after intake of meal is determined on the first test day for the healthy control group and the cancer group.
Secondly, the cancer patients in all 3 intervention arms are also measured after 10 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.
|
Before and acutely after 4 hours of feeding and the change after 10 weeks of supplementation
|
|
Fat-free mass
Time Frame: In postabsorptive state on test day 1 and the difference on test day 2, after 10 weeks of supplementation
|
Fat free mass is measured on the first test day for the healthy control group and the cancer group.
Secondly, the cancer patients in all 3 intervention arms are also measured after 10 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.
|
In postabsorptive state on test day 1 and the difference on test day 2, after 10 weeks of supplementation
|
|
Myofibrillar protein breakdown rate
Time Frame: Before and acutely after 4 hours of feeding and the change after 10 weeks of supplementation
|
The acute change 3-methylhistidine enrichment in plasma before and after intake of meal is determined on the first test day for the healthy control group and the cancer group.
Secondly, the cancer patients in all 3 intervention arms are also measured after 10 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.
|
Before and acutely after 4 hours of feeding and the change after 10 weeks of supplementation
|
|
Glycine rate of appearance
Time Frame: In the postabsorptive state on the first test day and the change on the second test day after 10 weeks of supplementation
|
Glycine enrichment in plasma is measured on the first test day for the healthy control group and the cancer group.
Secondly, the cancer patients in all 3 intervention arms are also measured after 10 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.
|
In the postabsorptive state on the first test day and the change on the second test day after 10 weeks of supplementation
|
|
Taurine turnover rate
Time Frame: In the postabsorptive state on the first test day and the change on the second test day after 10 weeks of supplementation
|
Enrichment of taurine in plasma is measured on the first test day for the healthy control group and the cancer group.
Secondly, the cancer patients in all 3 intervention arms are also measured after 10 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.
|
In the postabsorptive state on the first test day and the change on the second test day after 10 weeks of supplementation
|
|
Functional Status
Time Frame: On the first test day and the change on the second test day after 10 weeks of supplementation
|
Functional status will be assessed by the Karnofsky Performance Score, a widely used method to assess the functional status of a cancer patient.
It describes a patient's functional status as a comprehensive 11-point scale ranging from 0% to 100%.
|
On the first test day and the change on the second test day after 10 weeks of supplementation
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marielle PKJ Engelen, PhD, Texas A&M Univeristy
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012-0504
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer Patients Receiving Chemotherapy or Chemoradiotherapy
-
TerSera Therapeutics LLCCompletedOncology Patients Receiving ChemotherapyUnited States
-
Changhua Christian HospitalCommittee on Chinese Medicine and PharmacyUnknownCancer Patients Undergoing Chemotherapy or RadiotherapyTaiwan
-
Asoc. Prof. Erdoğan Selçuk ŞeberActive, not recruitingIs the Coronovac Vaccine Effective in Patients Receiving ChemotherapyTurkey
-
Firat UniversityCompletedBreast Cancer Patients Receiving ChemotherapyTurkey
-
Setenay BatırNot yet recruitingBreast Cancer Patients Receiving ChemotherapyTurkey
-
University Hospital, EssenCharite University, Berlin, Germany; University Hospital Heidelberg; Universitätsklinikum... and other collaboratorsCompletedPatients With Advanced Cancer Receiving Specialized Palliative CareGermany
-
Sun Yat-sen UniversityJiangsu Hansoh Pharmaceutical Co., Ltd.UnknownSolid Tumor Patients Receiving High Emetic Risk Multi-day ChemotherapyChina
-
Association Sud pour la Recherche en OncogériatrieCompletedColon Cancer Patients Receiving Chemotherapy in the Adjuvant or Metastatic Setting | Aged 70 or OlderFrance
-
Samsung Medical CenterUnknownPatients With Acute Myeloid Leukemia | Patients Receiving Induction/Consolidation ChemotherapyKorea, Republic of
-
Memorial Sloan Kettering Cancer CenterCompletedMetastatic Cancer or Locally Advanced | Patients Receiving Palliative RadiationUnited States
Clinical Trials on Daily intake for 10 weeks (+/- 2 weeks)
-
University Hospital Inselspital, BerneBaxter Healthcare CorporationCompletedHemodialysis | AnuriaSwitzerland
-
Asger Lund, MDUniversity of CopenhagenRecruitingType 1 Diabetes | Chronic Inflammation | Insulin SensitivityDenmark
-
Alfasigma S.p.A.CompletedChronic Intestinal Pseudo-obstructionBelgium, Italy, Spain
-
Laval UniversityActive, not recruitingMetabolic Syndrome | Gut MicrobiotaCanada
-
Norwegian University of Science and TechnologySt. Olavs HospitalCompletedCoronary Artery DiseaseNorway
-
Onorach Clinical LtdCompleted
-
Evandro Chagas Institute of Clinical ResearchAndrea Silvestre de SousaWithdrawnChronic Chagas DiseaseBrazil
-
Virginia Commonwealth UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart FailureUnited States
-
Fuji Yakuhin Co., Ltd.Completed
-
St. James's Hospital, IrelandUnknownVaricose VeinsIreland